Publication
Enhanced NRF1-mediated proteasome bounce-back and nelfinavir-mediated bortezomib sensitization in gemcitabine/cisplatin-resistant bladder cancer cells.
Atsumi Ota, Mina Kawai, Rin Himura, Sota Maruyama, Tomofumi Saka, Yuta Yoshino, Goki Yamada, Tadayuki Tsujita, Akira Ikari, Satoshi Endo
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Proteasome is an established therapeutic target in cancer, and proteasome inhibitors (PIs) such as bortezomib (BTZ) are clinically used for hematologic malignancies, including multiple myeloma. Although PIs have also been evaluated in solid tumors, their clinical efficacy has been limited. We…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available